The Gastrointestinal Cancer Channel is supported with funding from Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2025 | Single-agent divarasib shows activity in KRAS G12Cm solid tumors
Matthew Krebs, MD, PhD, University of Manchester, Manchester, UK, discusses results from Phase I studies of divarasib, a next-generation KRAS G12C inhibitor, in patients with KRAS G12C-positive pancreatic adenocarcinoma, cholangiocarcinoma, and other rare solid tumors. Divarasib demonstrated manageable safety with mostly low-grade adverse events, supporting divarasib as a promising targeted option for these difficult-to-treat cancers. This interview took place at the European Society for Medical Oncology (ESMO) 2025 Congress in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
